Literature DB >> 19639380

[Cardiac resynchronization therapy: is there always a need for the adjunctive ICD therapy?].

M Kullmer1, M Albanese, W Schöls.   

Abstract

Chronic postinfarction patients with an ejection fraction ≤ 30% and heart failure patients in NYHA classes II and III with an ejection fraction ≤ 35% due to ischemic or dilated cardiomyopathy meet current indications for ICD therapy. There is significant overlap with patients in NYHA class III also exhibiting a wide QRS complex (>120 ms), who commonly benefit from resynchronization therapy. Although a combination of ICD and CRT seems reasonable in many patients, one should be aware of subtle distinctions regarding selection criteria for either therapy. There is no clear ICD indication for heart failure patients in NYHA class IV or even III, taking subclass analysis of SCD-HeFT [4] into account. Uncertainty still exists for the subacute postinfarction phase (4 weeks to 6 months), whereas the early postinfarction phase should clearly not be considered for ICD evaluation. No randomized data exist for heart failure due to other etiologies. CRT, on the other hand, is not only helpful regarding symptom relief and quality of life, but also with respect to life expectancy. The additive value of adjunctive ICD therapy has not yet been proven in a randomized comparison. Finally, particularly in elderly patients, quality of life might seem more desirable than prevention of sudden cardiac death. Thus, combination of ICD and CRT is not always a "must". Instead, ICD guidelines still leave room for a patient specific decision, with "stand-alone" CRT still providing a very helpful, prognostically significant therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19639380     DOI: 10.1007/s00399-009-0054-5

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  25 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol.

Authors:  Arthur J Moss; Mary W Brown; David S Cannom; James P Daubert; Mark Estes; Elyse Foster; Henry M Greenberg; W Jackson Hall; Steven L Higgins; Helmut Klein; Mark Pfeffer; David Wilber; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

5.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

Review 6.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

7.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.

Authors:  S Adam Strickberger; John D Hummel; Thomas G Bartlett; Howard I Frumin; Claudio D Schuger; Scott L Beau; Cynthia Bitar; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

8.  Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.

Authors:  Inder S Anand; Peter Carson; Elizabeth Galle; Rui Song; John Boehmer; Jalal K Ghali; Brian Jaski; JoAnn Lindenfeld; Christopher O'Connor; Jonathan S Steinberg; Jill Leigh; Patrick Yong; Michael R Kosorok; Arthur M Feldman; David DeMets; Michael R Bristow
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

9.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

10.  Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study.

Authors:  John G F Cleland; Melanie J Calvert; Yves Verboven; Nick Freemantle
Journal:  Am Heart J       Date:  2009-01-20       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.